Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: A double-blind, randomized, placebo-controlled trial

American Journal of Clinical Nutrition

Volumn 83, Issue 4, 2006, Pages 754-759

  Schleithoff, Stefanie S ^a,b   Zittermann, Armin ^b   Tenderich, Gero ^b   Berthold, Heiner K ^c   Stehle, Peter ^a   Koerfer, Reiner ^b  

^a UNIVERSITY OF BONN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c Drug Commission of the German Medical Association   (Germany)

Author keywords

Congestive heart failure; Cytokine; Parathyroid hormone; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; COLECALCIFEROL; INTERLEUKIN 10; PARATHYROID HORMONE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; 25-HYDROXYVITAMIN D; DRUG DERIVATIVE; VITAMIN; VITAMIN D;

ADULT; ARTICLE; CALCULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BIOSYNTHESIS; BLOOD; CHRONIC DISEASE; DIET SUPPLEMENTATION; DISEASE COURSE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY;

CHRONIC DISEASE; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; PARATHYROID HORMONE; SURVIVAL RATE; TUMOR NECROSIS FACTOR-ALPHA; VITAMIN D; VITAMINS;

EID: 33646710998     PISSN: 00029165     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcn/83.4.754     Document Type: Article

References (30)

1. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
2. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
3. Bleumink GS, Knetsch AM, Sturkenboom MC, et al Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004;25:1614-9.
4. Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med 2002;347:1397-402.
5. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-7.
6. Swedberg K, Eneroth P, Kjekshus J, Snapinn S. Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group. Am J Cardiol 1990;66:40D-4D.
7. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-11.
8. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6.
9. Kubota T, Bounoutas GS, Miyagishima M, et al. Soluble tumor necrosis factor receptor abrogates myocardial inflammation but not hypertrophy in cytokine-induced cardiomyopathy. Circulation 2000;101:2518-25.
10. Zhu Y, Mahon BD, Froicu M, Cantorna MT. Calcium and 1alpha,25- dihydroxyvitamin D3 target the TNF-alpha pathway to suppress experimental inflammatory bowel disease. Eur J Immunol 2005;35:217-24.
11. Canning MO, Grotenhuis K, de Wit H, Ruwhof C, Drexhage HA. 1-alpha,25-Dihydroxyvitamin D3 (1,25(OH)(2)D(3)) hampers the maturation of fully active immature dendritic cells from monocytes. Eur J Endocrinol 2001;145:351-7.
12. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105-12.
13. Shane E, Mancini D, Aaronson K, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
14. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005;288:E125-32.
15. Standing committee on the scientific evaluation of dietary reference intakes, Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington DC: National Academy Press, 1997.
16. Zittermann A, Schwarz I, Scheld K, et al. Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J Clin Endocrinol Metab 2000;85:95-101.
17. Vieth R, Kimball S, Hu A, Walfish PG. Randomized comparison of the effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per day on biochemical responses and the wellbeing of patients. Nutr J 2004;3:8.
18. Vieth R. Vitamin D supplementation, 25-hydroxyvitamin D concentrations, and safety. Am J Clin Nutr 1999;69:842-56.
19. Zittermann A. Vitamin D in preventive medicine: are we ignoring the evidence? Br J Nutr 2003;89:552-72.
20. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 2005;10:94-111.
21. Zittermann A, Dembinski J, Stehle P. Low vitamin D status is associated with low cord blood levels of the immunosuppressive cytokine interleukin-10. Pediatr Allergy Immunol 2004;15:242-6.
22. Ohtsuka T, Hamada M, Hiasa G, et al. Effect of beta-blockers on circulating levels of inflammatory and anti-inflammatory cytokines in patients with dilated cardiomyopathy. J Am Coll Cardiol 2001;37:412-7.
23. Mallat Z, Besnard S, Duriez M, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:E17-24.
24. Koller-Strametz J, Pacher R, Frey B, Kos T, Woloszczuk W, Stanek B. Circulating tumor necrosis factor-alpha levels in chronic heart failure: relation to its soluble receptor II, interleukin-6, and neurohumoral variables. J Heart Lung Transplant 1998;17:356-62.
25. Muller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K. 1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood monocytes at the post-transcriptional level. Cytokine 1992;4:506-12.
26. Hewison M, Zehnder D, Chakraverty R, Adams JS. Vitamin D and barrier function: a novel role for extra-renal 1 alpha-hydroxylase. Mol Cell Endocrinol 2004;215:31-8.
27. Holick MF. Vitamin D. The underappreciated D-lightful hormone that is important for skeletal and cellular health. Curr Opin Endocrinol Diabetes 2002;9: 87-98.
28. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003;24:2054-60.
29. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999;56:383-92.
30. Ervin RB, Kennedy-Stephenson J. Mineral intakes of elderly adult supplement and non-supplement users in the third national health and nutrition examination survey. J Nutr 2002;132:3422-7.